Dexcom has announced that it has appointed Teri Lawver to its newly created role of chief commercial officer (CCO).
Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience.
Before joining San Diego–based Dexcom, Lawver spent two decades in a variety of leadership roles at Johnson & Johnson. Most recently, she served as worldwide VP, immunology at J&J’s Janssen Pharmaceutical Companies. Lawver also spent six years with J&J’s medical device companies and has experience in the diabetes space, serving as worldwide GM of Animas, an insulin delivery company acquired by J&J.
“I am thrilled to join Dexcom in the new chief commercial officer role and guide our talented team at this exciting time in the company’s history,” said Lawver.
To read more CLICK HERE
